Thrombolytic Therapy in Pulmonary Thromboembolism by Sidhu, Navdeep Singh & Kaur, Sumandeep
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Thrombolytic Therapy in 
Pulmonary Thromboembolism
Navdeep Singh Sidhu and Sumandeep Kaur
Abstract
Acute pulmonary thromboembolism (PE) is a common disorder with significant 
mortality and morbidity. Timely recognition and prompt therapy of this disorder is 
essential to prevent adverse consequences. Thrombolytic therapy has an important 
role in the management of high-risk pulmonary embolism patients, where it can be 
lifesaving. However, the potential clinical benefit of thrombolytic therapy needs to 
balanced against the risk of major bleeding associated with the use of these agents. 
Hence patient selection is of paramount importance in determining the success of 
this therapy. Management strategies in PE are centered around the concept of risk 
stratification of the cases. In this chapter we briefly discuss the risk categorization 
of PE cases, followed by a more elaborative discussion of the role of thrombolytic 
therapy in the management of patients with high risk or intermediate risk PE.
Keywords: pulmonary thromboembolism, embolism, thrombolysis, massive,  
high risk, sub-massive, intermediate risk, low risk, reperfusion, coronavirus, 
Covid-19
1. Introduction
Acute pulmonary thromboembolism (PE) is a frequent, often under-diagnosed 
disease with substantial in-hospital mortality and significant acute as well as long-term 
morbidity. Worldwide, venous thromboembolism (VTE), comprising of deep vein 
thrombosis (DVT) and PE, is the third most common acute cardiovascular syndrome 
after myocardial infarction and stroke [1]. The annual incidence rates of PE vary from 
39 to 115 per 100,000 population and of DVT vary from 53 to 162 per 100,000 popula-
tion, as estimated in epidemiological studies [2, 3]. Following the introduction of 
widespread use of D-dimer testing and computed tomography pulmonary angiography 
(CTPA) in 1990s, the estimated incidence of PE has increased significantly. A nation-
wide time trend analysis from United States has shown a substantial increase in inci-
dence of PE after introduction of CTPA (81% increase, from 62.1 to 112.3 per 100,000) 
[4]. Other longitudinal studies have shown a similar trend with increased rates of PE 
over time [5]. The overall incidence rates of PE are higher in males as compared to 
females (56 versus 48 per 100,000, respectively) [6, 7]. The incidence rates increase 
exponentially with increasing age, especially in women, such that rates are nearly eight 
times higher in individuals aged >80 years than in the fifth decade of life [2].
Pulmonary embolism ranks third among the causes of cardiovascular death, 
after myocardial infarction and stroke [3]. It is one of the leading preventable 
causes of death in hospitalized patients. In the United States, PE is responsible for 
nearly 100,000 deaths annually [3, 6–9]. Data from six European countries with 
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a total population of 454.4 million, has shown that in 2004, more than 370,000 
deaths were related to VTE [8]. Of these, 34% died abruptly, or within the first few 
hours of an acute event, before treatment could be started or take effect. In other 
patients, mortality resulted from acute PE that was diagnosed after death in 59% 
and in only 7% of the patients who died early, the correct diagnosis of PE was made 
before death [8]. Time trend analyses from North American, European, and Asian 
populations have suggested that case fatality rates of acute PE may be declining [3, 
10–15]. This positive impact on prognosis of acute PE appears to be related to more 
widespread use of effective therapies and interventions in the recent years [16, 17].
Prognosis from acute PE is related to the degree of obstruction and its hemody-
namic consequences. According to its severity, PE is usually divided into 3 catego-
ries as proposed by American Heart Association (AHA) and European Society of 
Cardiology (ESC) guidelines [18, 19]:
1. Massive (AHA) or high risk (ESC) PE: these hemodynamically unstable pa-
tients are characterized by the presence of cardiac arrest or persistent hypoten-
sion [defined as a systolic blood pressure (SBP) <90 mmHg and/or a fall in SBP 
of >40 mmHg for at least 15 minutes, or needing vasopressor support], with or 
without the evidence of end organ hypo-perfusion. These patients account for 
nearly 5% of hospitalized PE patients and have an average one-month mortal-
ity of around 30% [20].
2. Sub-massive (AHA) or intermediate risk (ESC) PE: These patients are identi-
fied by the presence of right ventricle (RV) strain without hypotension. RV 
strain includes RV dysfunction on echocardiography or CTPA [right/left ven-
tricular (LV) ratio > 0.9] or RV injury and pressure overload with an increase 
in the level of cardiac biomarkers like troponins or brain natriuretic peptide 
(BNP). There are some differences in the AHA and ESC guidelines pertaining 
to this category of patients. The criterion for sub-massive PE in AHA guidelines 
is the presence of RV strain without hypotension. The ESC criteria of interme-
diate-risk PE are more broader and include patients with a simplified Pulmo-
nary Embolism Severity Index (sPESI) score ≥ 1 (i.e., age > 80 years; cancer, 
chronic heart failure or chronic pulmonary disease; heart rate > 110 bpm; SBP 
<100 mm Hg; or arterial oxygen saturation < 90%), regardless of presence of 
RV strain. The ESC further subcategorizes these patients into 2 sub-groups 
depending on the presence of both RV dysfunction and RV injury (intermedi-
ate risk—high) or only one or neither of these (intermediate risk—low). These 
patients with sub-massive or intermediate-risk PE constitute about 35–55% 
of hospitalized PE patients and the short-term mortality rates in this hetero-
geneous group vary from 2 to 3% over a period of 7 to 30 days in prospective 
randomized clinical trials [21], to 3–15% over a period of 7 to 90 days in obser-
vational cohort studies [22–24].
3. Low risk (AHA and ESC) PE: These are the patients of PE who do not meet the 
criteria for sub-massive (AHA) or intermediate-risk (ESC) PE. These account 
for 40–60% of hospitalized PE patients and have an estimated mortality of 
around 1% within 1 month [25].
Timely risk stratification of a patient with acute PE is essential for determin-
ing the optimal therapeutic approach. Low risk PE patients are typically managed 
with anticoagulation alone. In massive or high-risk PE patients and some selected 
high-risk patients in the sub-massive or intermediate risk category early reperfusion 
therapy is the need of hour, which can be lifesaving. Primary reperfusion therapy 
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in most cases is systemic thrombolysis. Alternative reperfusion therapies include 
surgical embolectomy or percutaneous catheter-directed treatments, which are pri-
marily used in patients with contraindications to systemic thrombolysis, depending 
upon the local availability and expertise [19]. In the following sections, we discuss 
the role of systemic thrombosis in the treatment of acute PE.
2. Use of thrombolytic therapy in acute pulmonary embolism
2.1 Decision to thrombolyse
In pulmonary embolism, thromboembolic obstruction of the pulmonary 
arterial tree with the resultant increase in right ventricular afterload is the central 
pathophysiologic process leading to the development of hemodynamic instabil-
ity and possible mortality. Rapid removal of the clot, either pharmacologically or 
surgically results in prompt restoration of pulmonary circulation and decrease in 
pulmonary arterial pressures [26]. Thrombolysis has been shown to result in more 
rapid restoration of pulmonary perfusion as compared to anticoagulation alone, 
with resultant improvement in hemodynamics and right ventricular function. This 
positive impact of thrombosis on hemodynamics is limited to the initial few days. In 
patients surviving acute PE, these differences are no longer noted at one week after 
the therapy [27].
Decision to thrombolyse a patient with acute PE is of critical importance which 
requires a good judgment about the benefit–risk ratio of thrombolytic therapy. 
Instituting thrombolytic therapy in a sick patient with persistent hypotension or 
shock who is at low bleeding risk can prevent a potential mortality; whereas its use 
in an intermediate risk patient with high bleeding risk can have devastating bleeding 
consequences. Given the inherent difficulties in this decision making, many centers 
and society guidelines have advocated the formation of Pulmonary Embolism 
Response Teams (PERTs) for the management of high risk and selected cases of 
intermediate risk PE patients [19]. These teams could consist of specialists from dif-
ferent fields like cardiology, pulmonary, intensive care/anesthesiology, hematology, 
cardiac surgery, vascular medicine and interventional radiology, depending upon 
the local availability. This facilitates timely decision making in a particular case, with 
quick formulation of a treatment strategy and its implementation.
Thrombolysis is typically considered in a hemodynamically unstable patient who 
has a confirmed or highly suspected acute PE and who has a favorable risk–benefit 
ratio with a low bleeding risk. Diagnosis is usually made on the basis of findings of 
CTPA, although, ventilation-perfusion scans or catheter pulmonary angiography 
can also be confirmatory. Sometimes, the thrombolytic therapy is instituted on 
making the diagnosis by a bedside echocardiogram when patient is too sick to be 
shifted for CTPA or if it is not available immediately. Very infrequently, thrombo-
lytic therapy may be started during cardiopulmonary resuscitation in a patient with 
high clinical suspicion of PE, although it is rarely effective in cases of refractory 
pulseless activity arrest.
Thrombolysis in PE is most effective when stated within 48 hours of symptom 
onset, but can still be potentially useful for up to 14 days of symptom onset in 
selected patients [19].
2.2 Thrombolysis in massive or high-risk PE
The most widely accepted indication of thrombolysis in acute PE is the presence 
of high risk or massive PE [18, 19, 28, 29]. These recommendations are supported by 
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the findings of a small randomized controlled trial which compared thrombolytic 
therapy (streptokinase) followed by heparin or heparin alone in eight patients with 
massive PE. In this study, the thrombolytic therapy was found to be associated with 
significant reduction in mortality as compared to heparin alone [30].
2.3 Thrombolysis in sub-massive or intermediate risk PE
Thrombolysis in this category of PE is controversial and often requires an 
individualized approach to the patient. The current evidence does not support the 
routine use of thrombolytic therapy in these patients, although rescue thrombolysis 
is indicated in patients who have hemodynamic deterioration while being treated 
with anticoagulants [18, 19, 28, 29].
Nevertheless, thrombolysis in these patients has been associated with reduced 
chances of hemodynamic compromise and possibly, reduced risk of long-term 
complications including chronic thromboembolic pulmonary hypertension 
(CTEPH) [31], albeit, at the cost of increased bleeding events including intracranial 
hemorrhage.
There have been many studies which have tried to explore the role of thrombolytic 
therapy in this group of patients. The largest among these is the Pulmonary Embolism 
Thrombolysis (PEITHO) trial, a randomized double blind trial of 1005 patients [31]. 
It randomized normotensive patients with intermediate risk PE to either tenecteplase 
plus heparin or placebo plus heparin. To be eligible for this trial, the intermediate risk 
PE patients needed to have evidence of right ventricular dysfunction on echocardiog-
raphy or CTPA along with elevated levels of cardiac troponins. The primary outcome 
of death or the development of hemodynamic compromise within 7 days occurred in 
2.6% of the patients in tenecteplase group as compared to 5.6% in the placebo group 
(odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; p = 0.02). Up to 7 days of 
randomization, the mortality was not significant different between the groups (1.2% 
in tenecteplase group vs. 1.8% in placebo group, p = 0.42). The benefit of decreased 
primary outcome in this study came at the cost increased risk of major extra-cranial 
(6.2% in tenecteplase group vs. 1.2% in placebo group, p < 0.001) and intra-cranial 
bleeding (2% in tenecteplase group vs. 0.2% in placebo group, p = .003). On follow-
up of up to 30 days, the death rate was not statistically significant between the groups 
(2.4% in tenecteplase group vs. 3.2% in placebo group, p = 0.42). Thus, in this study 
thrombolytic therapy decreased the incidence of development of hemodynamic 
compromise but had no impact on 7 days and 30 days mortality.
Other studies conducted in this field have been limited by smaller sample size of 
the study population, thus necessitating the use of composite outcome end-points. 
The management strategies and prognosis of pulmonary embolism (MAPPET-3) 
trial randomized 256 normotensive PE patients with pulmonary hypertension or 
RV dysfunction to receive either heparin plus alteplase or heparin plus placebo. 
The primary outcome of in-hospital mortality or clinical deterioration requiring 
an escalation of treatment, was significantly lower in thrombolytic group (11% 
vs. 24.6%, p = 0.006), and the thrombolytic group had higher the probability 
of 30-day event free survival by Kaplan-Meir estimates (p = 0.005). The differ-
ence in the primary outcome was largely due to higher number of patients in the 
heparin group requiring escalation of the treatment, with no significant differ-
ence in mortality. The incidence of fatal bleeding or hemorrhagic stroke was not 
significantly different between the groups [32]. Moderate Pulmonary Embolism 
Treated with Thrombolysis (MOPETT Trial) randomized 121 patients with 
moderate PE to receive low dose thrombolytic therapy plus anticoagulation or 
anticoagulation alone. In this study, the thrombolytic therapy was associated with 
a significant reduction of pulmonary hypertension which was maintained up to 
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28 months, although there was no difference in mortality [33]. The North American 
Tenecteplase or Placebo: Cardiopulmonary Outcomes at Three Months (TOPCOAT) 
trial also explored the use of thrombolytic therapy in patients with sub-massive PE 
[34]. This study had different design as compared to the contemporary PEITHO 
trial with broader definition of submissive PE which allowed inclusion if there was 
evidence of RV hypokinesis on echocardiography or there were elevated cardiac 
biomarkers (cardiac troponin I/T or BNP/NT-pro BNP). This trial had to be pre-
maturely terminated due to relocation of the principal investigator and thus only 
83 patients could be randomized. The primary outcome at 5 days (a composite of 
death, circulatory shock, intubation, or major bleeding) was seen in one patient in 
thrombolytic arm and three patients in the heparin arm.
There have been many systematic reviews and meta-analyses published regard-
ing the use of thrombolysis in patients with sub-massive or intermediate PE. One 
such analysis by Chatterjee et al. in 2014, included 16 RCTs with 2115 patients of 
both massive (or high risk) and sub-massive (or intermediate risk) PE patients. 
This analysis reported a lower all-cause mortality in thrombolytic group (odds 
ratio 0.53, 95% confidence intervals 0.32–0.88), although with a greater risk of 
major bleeding (odds ratio 2.73, 95% confidence intervals 1.91–3.91). In a sub-set 
of 1775 patients from 8 trials of intermediate risk PE, it was noted that systemic 
thrombolytic therapy was associated with reduction in mortality in intermediate 
high-risk PE patients with RV dysfunction as compared to anticoagulation alone 
(odds ratio 0.48, 95% confidence intervals 0.25–0.92), but at the cost of increased 
major bleeding events (odds ratio 3.19, 95% confidence intervals 2.07–4.92) [21]. A 
recently published meta-analysis by Zuo et al. in 2021, included 21 trials with a total 
of 2401 patients with both stable and unstable PE. The results showed that throm-
bolytic therapy followed by heparin was associated with lower risk of death (odds 
ratio 0.58, 95% confidence intervals 0.38–0.88) and recurrent PE (odds ratio 0.54, 
95% confidence interval 0.32–0.91). However, the evidence was of low certainty for 
both of these outcomes as the effects weakened significantly after the exclusion of 
one study with high risk of bias. Thrombolytic therapy was associated with higher 
risk of major bleeding (odds ratio 2.84, 95% confidence intervals 1.92–4.20) and 
hemorrhagic stroke (odds ratio 7.59, 95% confidence intervals 1.38–41.72) [35].
Given the equivocal nature of the clinical evidence till date, the decision to 
thrombolyse a patient with sub-massive or intermediate PE should be individual-
ized with careful consideration of the benefit–risk ratio. The AHA 2011 guidelines 
support the use of thrombolytic therapy in sub-massive PE cases who have clinical 
evidence of adverse prognosis (new hemodynamic instability, deteriorating respira-
tory failure, severe RV dysfunction, or major myocardial necrosis) and low risk of 
bleeding (Class IIb; Level of Evidence C) [18]. The 2016 CHEST guidelines recom-
mend against the use of thrombolytic therapy in acute PE without hypotension 
(grade 1B) [28]. Similarly, the ESC 2019 guidelines and 2020 American Society of 
Hematology (ASH) guidelines recommend against the routine use of thrombolytic 
therapy in patients with intermediate risk or sub-massive PE [19, 29].
2.4 Thrombolytic agents and their dosing
The approved thrombolytic agents and their dosing in PE has been shown in 
Table 1.
To date, no studies have been shown the superiority of one agent over the other in 
this patient population. The ease of administration coupled with the non-availability 
of first-generation agents (streptokinase and urokinase), has made recombinant 
tissue-plasminogen activator (rt-PA, alteplase) as the favored agents in most of the 
developed world; however, given their lower costs, the first-generation agents are still 
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widely used in the developing world. Unfractionated heparin (UFH) may be continued 
during the infusion of rt-PA but it should be with-held during the infusion of strep-
tokinase or urokinase [19]. Other investigational thrombolytic agents for use in PE 
include tenecteplase, reteplase, desmoteplase, but none has been approved as yet [19].
2.5 Contraindications to thrombolysis
The major contraindications to thrombolytic therapy are listed in  Table 2.
2.6 Assessment of response to therapy
This is usually done by continued clinical monitoring of the patient for improve-
ment in signs and symptoms (e.g., improved blood pressure, reduced respiratory 
Absolute contraindications
• History of hemorrhagic stroke or stroke of unknown origin
• Ischemic stroke in last 6 months
• Intracranial neoplasm or structural cerebral vascular lesion
• Major trauma, surgery or head injury in last 3 weeks
• Active bleeding (excluding menstrual bleeding)
• Bleeding diathesis
• Suspected aortic dissection
Relative contraindications
• Severe uncontrolled hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
• History of poor controlled hypertension in the past
• Transient ischemic attack in last 6 months
• Current use of oral anticoagulants
• Pregnancy or first week post-partum
• Non-compressible vascular puncture sites
• Age more than 75 years
• Advanced liver disease
• Active peptic ulcer disease
• For streptokinase or urokinase: previous exposure (more than 5 days ago) or previous allergic reaction to 
these agents
Table 2. 




100 mg in 2 hours, accelerated regimen 0.6 mg/kg over 15 mins 
(maximum dose 50 mg)
Streptokinase 250,000 IU loading dose over 30 mins, followed by 100,000 IU/h for 
12–24 h; accelerated regimen 1.5 million IU over 2 h
Urokinase 4400 IU loading dose over 10 mins, followed by 4400 IU/kg/h over 
12–24 h; accelerated regimen: 3 million IU over 2 h
Table 1. 
Approved thrombolytic agents and their dosing in pulmonary embolism [19].
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rate or heart rate, improvement in oxygenation). Some centers advocate serial 
echocardiograms to evaluate for improvements in pulmonary artery pressures and 
RV dysfunction. Although RV size and function may improve acutely, but often it 
may lag behind the signs of clinical improvement by several weeks to months. After 
thrombolytic therapy the patient is transitioned to long term anticoagulant therapy 
depending upon the etiology.
2.7 Role of low dose thrombolytic therapy
The disappointingly high rates of intra-cranial hemorrhage in the PEITHO 
trial, led many investigators to explore the use of low-dose thrombolytic therapy 
in patients with PE. The widely recommended rt-PA dose of 100 mg over 2 hours 
is largely based from experience from the patients with myocardial infarction. 
Many researchers have argued that lungs may be an organ with higher sensitiv-
ity to thrombolytic therapy as compared to the myocardium and given that lungs 
receive the entirety of cardiac output as compared to only 5% being received by the 
coronary circulation, low-dose thrombolytic therapy in PE seems to be a logical 
approach. Low-doses thrombolytic therapy could be especially useful in elderly 
patients, pregnant patients and in those who have relative contraindications.
A multicenter RCT by China VTE group published in 2010, randomized 118 
patients with either hemodynamic unstable or anatomic massive pulmonary 
obstruction to full dose (100 mg/2 h) rt-PA regimen or half dose (50 mg/h) rt-PA 
regimen. Half-dose regimen was associated with similar improvements in RV 
function, lung perfusion defects and pulmonary artery obstruction, and had lesser 
bleeding complications especially in patients with body weight of less than 65 
kgs [36]. The subsequent MOPETT trial (as described above) published in 2013, 
demonstrated significant lower risk of progressive pulmonary hypertension in low-
dose thrombolytic arm, albeit with a similar mortality [34]. Another study of 66 
patients with intermediate risk PE, randomized patients to receive either low dose 
rt-PA (30 mg/2 h) plus low-molecular weight heparin (LMWH) or LMWH alone. In 
this study, the thrombolytic group had significant reductions in pulmonary artery 
systolic pressures (PASP) and the RV/LV ratio as compared to the baseline. There 
was no significant change in these parameters from the baseline in LMWH group. 
Thrombolytic therapy resulted in significant decrease in PASP and an improved 
symptom severity as compared to LMWH group. On follow up of 90 days, no sig-
nificant difference was noted in terms of mortality, recurrent venous thromboem-
bolism or major bleeding, although, thrombolytic group had more minor bleeding 
and less hemodynamic decompensation [37]. In a recently published prospective, 
non-randomized open label, single center study of 76 patients with intermediate 
risk PE, half dose rt-PA (50 mg/2 h) plus LMWH was compared to LMWH alone. It 
was found that half dose rt-PA significantly prevented mortality or hemodynamic 
deterioration at 7 days and 30 days without increase in bleeding risk [38]. Thus, the 
results from these small studies suggest that low dose thrombolytic therapy may 
be an attractive option in the treatment of PE, however, larger RCTs are needed to 
draw definite conclusions on this topic.
2.8 Thrombolysis in pulmonary embolism related to Covid-19
Coronavirus disease-19 (Covid-19) is associated with a significantly increased 
risk of procoagulant events including PE, the risk being highest in critically ill 
patients with severe disease admitted to intensive care units (ICUs) [39]. The 
development of PE in patients with Covid-19 is associated with worse outcomes, 
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robust data from large studies, the Global COVID-19 Thrombosis Collaborative 
Group currently advocates managing PE in Covid-19 on the similar lines as patients 
of non-Covid PE [41]. Systemic thrombolysis is recommended for patients with 
Covid-19 related PE in case of massive or high-risk PE; or in patients with sub-
massive or intermediate PE who develop hemodynamic deterioration while being 
treated with anticoagulant therapy. However, there are few peculiarities of this situ-
ation which demand careful consideration. Firstly, it is often difficult to disentangle 
the hemodynamic consequences of PE in a sick Covid-19 patient from those of 
severe pneumonia and acute respiratory distress syndrome (ARDS); thus, neces-
sitating critical thinking and judgment. Secondly, Covid-19 is often associated with 
an unfamiliar coagulopathy with the presence of thrombocytopenia in a sizeable 
proportion of the patients which increases the risk of bleeding complications from 
systemic thrombolysis [42]. Presence of co-existent thrombocytopenia calls for 
an individualized approach in such patients and many researchers have advocated 
the use of catheter directed thrombolysis as the potential first line therapy in these 
patients [43]. Further evidence from larger studies is needed in this field to guide 
decision making.
3. Conclusions
Acute PE is a frequent disorder which needs timely recognition and management 
to ensure good outcomes. Thrombolytic therapy plays a central role in the manage-
ment of patients with massive (or high-risk) PE, where it can be lifesaving. This 
therapy can also be useful in improving outcomes in carefully selected patients with 
sub-massive (or intermediate risk) PE.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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